[Date Prev] | [Thread Prev] | [Thread Next] | [Date Next] -- [Date Index] | [Thread Index] | [List Home]
Subject: RE: [dita] RE: [dita-pharma] Future of the "DITA for Pharmaceutical Content" subcommittee
It is interested to hear that. I do not know much about Pharmaceutical Content but it is welcoming I think.
Hayashi-san, let’s have a meeting soon. I want to hear more about!
Hi Kris and Don,
I’ve known that Ole and his company has been successful over the years. This might be a good thing for DITA market in Japan, extending this industry.
-Tetsuya, InfoParse, Inc.
Dear Kristen James Eberlein,
I am Masahiro Hayashi, a member of Pharmaceutical Content Subcommittee.
We held the XML & DITA Seminar which is specialized to focus on Pharmaceutical Industry yesterday on 8/24.
Japanese Pharmaceutical company and I made a presentation before presentation & demonstration of XML tool vendor.
My friend of Japanese Pharmaceutical company was talking about current status of eCTD (eSubmission) and old & new document comparison
for Pharmaceutical documents using XML tool.
And I was sharing about DITA & Pharmaceutical and introduction of Sanofi’s case study which was presented at ShareFEST2012 in Philadelphia.
The seminar was going successfully. Moreover, everybody of the Pharmaceutical companies got with interest very much in DITA.
I am not good at a role of a leader of DITA Pharmaceutical Content Subcommittee(PCS) because of communication(English) skill,
But I hope that I can contribute something for a while.
So, I would like to ask you to revitalize and continue PCS.
That is a small request from Japan.
DITA Exchange™ Wins 2012 Microsoft Life Sciences Innovation Award
Don Day and I are pleased to see a growing interest in DITA across the pharmaceutical industry. A number of pharmaceutical companies have implemented DITA to evaluate the standard, and the Drug Information Association (DIA) included a session titled "Implementing Structured Authoring: Understanding the DITA Model and Its Applicability for Content and Metadata Management" in their annual meeting this year (see http://tinyurl.com/cxcnpbm).
At OASIS request, we are closing subcommittees that either are inactive or have completed their work. As TC chairs, Don Day and I are considering closing the Pharma subcommittee, but before we do so, we wanted to shout out to SC members and the TC members at-large to see if there are any individuals interested in stepping forward and leading this subcommittee and its work effort.
Let us know if you have time and ability to provide leadership for this subcommittee. Otherwise, we'll make a motion to close the subcommittee at a future TC meeting. (The subcommittee always can be reactivated at a time when there is leadership and a group of committed members.)
Kristen James Eberlein
Principal consultant, Eberlein Consulting
+1 919 682-2290; kriseberlein (skype)